GlycoVaxyn AG

Shigella4V’s story began at LimmaTech, which spun out from GlycoVaxyn after its 2015 acquisition by GSK. Valneva has added to its growing arsenal of vaccines by handing over 10 million euros ($10.7 million) upfront to LimmaTech for the global license to a Shigella candidate that once formed part of a GSK partnership.There is no vaccine approved for Shigella, the second leading cause of fatal diarrheal disease worldwide. LimmaTech’s asset, dubbed Shigella4V, is a tetravalent bioconjugate vaccine that produced some positive interim data from a phase 1/2 trial in February.As well as the upfront fee, LimmaTech will be in line for an undisclosed amount of milestone payments and low double-digit royalties on sales should Shigella4V make it to market. The deal means that LimmaTech will be responsible for conducting a pair of phase 2 trials launching later this year: a controlled human infection model and a pediatric study in low- and middle-income countries, which are worst affected by Shigella. “We are very pleased to partner with LimmaTech to advance a promising program in an area of high unmet medical need,” Valneva CEO Thomas Lingelbach said in the August 1 release.“The Shigella vaccine candidate enables a potential first-in-class vaccine solution for both [low and middle-income countries] and travelers and, as such, represents a potentially highly synergistic product for Valneva,” Lingelbach continued. “The anticipated development path follows a staggered and risk-mitigated strategy, and hence allows an efficient capital allocation in line with our communicated plan of having a new R&D program in phase 3 by 2027.” Shigella4V’s story began at LimmaTech, which spun out from GlycoVaxyn after its 2015 acquisition by GSK. When GSK acquired GlycoVaxyn, the candidate was added to the pipeline and LimmaTech was offered a research agreement to develop new bioconjugate antigen-based vaccines in partnership with the U.K.'s non-profit Wellcome Trust. A year ago, GSK handed back the candidate, citing plans to prioritize its own vaccine for the bacteria.“Having developed the S4V Shigella vaccine candidate from its early discovery phase to the promising clinical data we achieved to date, we are excited to accelerate the program with our partnership with Valneva,” LimmaTech CEO Franz-Werner Haas said in the August 1 release.Having missed the boat with a COVID-19 vaccine that was only approved in the U.K. in 2022, Valneva has been expecting more success with the rollout of its chikungunya virus vaccine this year. The French biotech also markets shots for cholera and Japanese encephalitis, with candidates for Lyme disease and Zika in the clinic.

Paris (France), 2nd May 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of Roman Fleck as Chairman of the Board. Yann Gaston-Mathé steps down of his role as Chairman to focus on his CEO duties. Roman Fleck holds an MBA from New York University (Sterne School of Business) and received a PhD in organic chemistry from MIT (Massachusetts Institute of Technology), USA. He began his career as a principal scientist with Boehringer Ingelheim Pharmaceuticals, where he led drug development projects in oncology, inflammation and cardiovascular disease. After that he joined investment firm Index Ventures Life Sciences, which became Medicxi Ventures in 2014. He has notably invested in GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS) and Novocure (NASDQ: NVCR). He represented Medicxi Ventures on the boards of these companies. From 2017 to 2022, he was CEO of Janpix, Ltd, an oncology-focused biotech that became part of Centessa Pharmaceuticals in 2021. Roman is currently Chairman of HDAX Therapeutics, a biotech focused on CNS (central nervous system), and an Independent Board Member at ReColony, a microbiome focused company. Roman Fleck appointed Chairman of Iktos’ Board of Directors Roman Fleck is the author of numerous publications in prestigious scientific journals. He has filed over 20 patents in the course of his career. Roman Fleck, Chairman of the Supervisory Board, comments: “I am delighted to join the Board of Iktos, a pioneering company which has been advancing AI-driven drug discovery since 2016. Since then, Iktos has developed a technology platform which allows it to offer comprehensive drug discovery solutions to its clients that are unique in the industry. I look forward to sharing my insights and supporting Yann & Iktos as it continues to advance its strategy and builds upon its position as a leader in the field.” Yann Gaston-Mathé, co-founder and CEO of Iktos, comments: "Roman has an exceptional professional background with unvaluable experience in pharmaceutical research, investment and company leadership. We are delighted that he has agreed to chair Iktos’ Board of Directors. His deep understanding of the biotech industry and broad network within the investment and pharma communities will be a strategic advantage for the development of Iktos. At a personal level, I look forward to working closely with Roman and learning from his experience." -- About IktosIncorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.More information on: http://www.iktos.ai/ Press contactsIktos: Yann Gaston-Mathé (CEO) - contact@iktos.com Ulysse CommunicationNicolas Daniels – ndaniels@ulysse-communication.com / + 33 6 63 66 59 22Iva Baytcheva – ibaytcheva@ulysse-communication.com / + 33 6 28 59 07 03 Attachments Iktos Roman Fleck CP Iktos_Nomination Roman Fleck VE VDef

SCHLIEREN, Switzerland--(BUSINESS WIRE)-- LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea. Later-stage clinical development efforts will focus on the company’s Shigella vaccine program, which LimmaTech developed as part of a joint collaboration with GSK and recently exclusively in-licensed. The company expects to announce preliminary results from the Shigella program’s ongoing Phase 2 clinical trial in the second half of 2023. As part of the company’s next phase of corporate growth, LimmaTech also welcomed seasoned biotech industry leader Dr. Franz-Werner Haas as CEO. Concurrent with the financing, Kabeer Aziz from Adjuvant Capital, Zina Affas Besse, PhD, from AXA IM Alts, and Camilla Petrycer Hansen, PhD from Novo Holdings will join LimmaTech’s Board of Directors. "Within the next decade, multiple bacterial infections will become untreatable due to antimicrobial resistance, which is already a significant burden on global health. By advancing our innovative technology platform, LimmaTech has the potential to simultaneously provide vaccine-induced protection against bacterial infections, mitigate the increasing risk of antibiotic resistance, and move toward the control of several highly transmissible pathogens,” said Dr. Franz-Werner Haas, CEO of LimmaTech. “Our Series A with backing from highly experienced and strategic institutional investors reflects the increasing value of our technology and our achievements to date. With this support and our team of proven experts in bacterial vaccine development and manufacturing, we look forward to providing life-changing vaccines to address a major global medical need.” Kabeer Aziz, Partner at Adjuvant Capital, commented: “Each of the firms co-leading this financing is dedicated to using venture capital investments to support bold and innovative companies like LimmaTech that are developing technologies with the potential to generate significant improvements in global public health. Given the deadly threat posed by increasingly treatment-resistant pathogens, and the enormous scale of the problem, vaccines targeting these indications represent highly attractive commercial markets as well.” Zina Affas Besse, Partner, Deputy Head of Healthcare, Private Equity, at AXA IM Alts, further commented: “Our investment in LimmaTech through our healthcare private equity strategy supports our wider goal of investing in companies with innovative and affordable solutions to global health challenges and we are proud to collaborate with this outstanding team of biotech industry veterans. LimmaTech’s leadership team has a long track record of success, having built two vaccine technology platforms with programs in late-stage clinical development. We are happy to support LimmaTech in growing its pipeline of much-needed vaccine candidates and contributing to improving health globally.” Camilla Petrycer Hansen, Principal at Novo Holdings and REPAIR Impact Fund, said: “Our investment in LimmaTech reflects Novo Holdings’ continued commitment to tackling antimicrobial resistance. We believe that with its outstanding record of success in the vaccine field, its seasoned leadership at the helm, and its promising technology, LimmaTech represents a very attractive investment opportunity, which we are pleased to pursue in partnership with leading investors. We are thrilled to support LimmaTech’s pipeline of much-needed vaccine candidates with the potential to significantly improve health outcomes globally.” The Series A is the first venture-backed round of funding for LimmaTech since it was spun out of GlycoVaxyn, its predecessor company that was acquired by GSK in 2015. LimmaTech’s leadership team has in-depth bacterial vaccine development and manufacturing expertise, having sponsored, and led several clinical trials around the world. LimmaTech's unique technology platforms are all based on E. coli expression systems. These technologies allow the production of multivalent vaccines combining carbohydrates and protein antigens with broad and novel modes of action. The company’s overall objective is to develop and manufacture highly effective vaccines that can stop the spread of infections caused by emerging antimicrobial resistance. About Antimicrobial Resistance (AMR) AMR is responsible for approximately 5 million deaths annually.1 Nearly one million of these deaths occur in children under the age of five, and these numbers are rising at an alarming rate. Treatment with antibiotics has historically been able to reliably stop bacteria from growing or kill these pathogens, however, inappropriate or excessive use of antibiotics has caused bacteria to develop natural resistance to these agents. As a result, infections that were once easily treatable have now become difficult, if not impossible, to cure. As a leading example of this threat to global health, half of the approximately 700,000 annual2 gonorrhea infections in the U.S. are already resistant to antibiotics as of today, and there is a real threat of gonorrhea soon becoming untreatable.3 This development is also projected for a growing number of other infections, such as Shigella sp., in both developed and low- and middle-income countries. The United States Centers for Disease Control and Prevention has identified AMR as a serious threat to public health due to its resistance to reserve antibiotics. Shigella sp. is responsible for approximately 450,0004 infections in the U.S. alone, and 700,0005 deaths globally each year. For children, it is the most common bacterial cause of diarrheal death worldwide.6 The discovery of new antibiotics, while promising, has not kept pace with the growth of AMR, making the development of vaccines against pathogens with concerning multidrug-resistant patterns an essential component of any strategy to contain this deadly global health threat. About LimmaTech Biologics AG LimmaTech Biologics AG is applying its deep know-how of engineering complex molecules to develop next-generation vaccines to prevent life-threatening diseases. Spun out from GlycoVaxyn after that company’s acquisition by GSK, LimmaTech Bio is advancing its own proprietary clinical pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance such as gonorrhea, alongside partnered programs with GSK. LimmaTech is committed to translating novel scientific concepts into highly effective vaccines that benefit humanity. For more information, please visit About Adjuvant Capital Headquartered in New York, with offices in Zürich, Adjuvant is a global life science investment fund built to accelerate the development of new technologies for the world's most pressing public health challenges. Backed by prominent healthcare and emerging market investors, Adjuvant draws upon its network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify new investment opportunities. Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics, and medical devices targeting high-burden infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, with a commitment to make these interventions accessible globally. For more information, visit About the REPAIR Impact Fund The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund was established by Novo Holdings in 2018 with a purpose to increase humanity’s therapeutic arsenal in the fight against antimicrobial resistance. With a total commitment of USD 165 million, the Fund invests in start-ups, early-stage companies and corporate spin-outs in Europe and the United States and gives priority to first-in-class therapies, covering small molecules, biologics and new modalities, from the early stage of drug development to the early stages of clinical development. The Fund focuses on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 18 families of bacterial and fungal pathogens that pose the greatest threat to human health. For more information: REPAIR Impact Fund · Home (repair-impact-fund.com) Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. For more information: 1 Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet (London, England), 399(10325), 629–655. (21)02724-0 2 Center for Disease Control and Prevention. (May 16,2023). National Overview of STDs, 2021. Retrieved August 31, 2023, from 3 Alirol, E., Wi, T. E., Bala, M., Bazzo, M. L., Chen, X. S., Deal, C., Dillon, J. R., Kularatne, R., Heim, J., Hooft van Huijsduijnen, R., Hook, E. W., Lahra, M. M., Lewis, D. A., Ndowa, F., Shafer, W. M., Tayler, L., Workowski, K., Unemo, M., & Balasegaram, M. (2017). Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS medicine, 14(7), e1002366. 4 Center for Disease Control and Prevention (April 6, 2023). Questions & Answers. Retrieved August 31, 2023, from 5 World Health Organization. (March 24, 2023). Extensively drug-resistant Shigella sonnei infections - Europe - European Region (EURO). Retrieved August 31, 2023, from 6 Fleming, J. A., Gurley, N., Knudson, S., Kabore, L., Bawa, J. T., Dapaah, P., Kumar, S., Uranw, S., Tran, T., Mai, L. T. P., Odero, C., Obong'o, C., Aburam, K., Wanjiru, S., Hanh, N. T. M., Dung, L. P., & Hausdorff, W. P. (2023). Exploring Shigella vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings. Vaccine: X, 15, 100368. View source version on businesswire.com: Contacts LimmaTech Biologics Franz-Werner Haas, CEO E-Mail: media@lmtbio.com For media inquiries Gretchen Schweitzer or Alexander Siebert Trophic Communications Phone: +49 1511 0619 905 E-Mail: limmatech@trophic.eu Source: LimmaTech Biologics AG View this news release online at: